2011
Clinical Predictors of All-Cause In-Hospital Mortality In Patients with Sickle Cell Disease in the United States- First Reported Results From A Nationally Representative Sample
Goel R, Gupta A, Krishnamurti L. Clinical Predictors of All-Cause In-Hospital Mortality In Patients with Sickle Cell Disease in the United States- First Reported Results From A Nationally Representative Sample. Blood 2011, 118: 339. DOI: 10.1182/blood.v118.21.339.339.Peer-Reviewed Original ResearchSickle cell diseaseHospital mortality rateIn-Hospital MortalityClinical predictorsCell diseaseHospital mortalityHospital dischargeClinical factorsIndependent predictorsNationally Representative SampleRelated hospitalizationsSCD patientsExchange transfusionMortality rateICD-9-CM diagnosis codesNationwide Inpatient Sample databaseMultivariable logistic regression modelDiagnosis of SCDAcute chest syndromePredictors of mortalityRed cell transfusionDevelopment of sepsisPatients' socioeconomic statusMultivariable logistic regressionSignificant independent predictors
2010
Does Deep Venous Thrombosis as Primary Admitting Diagnosis Represent Different Etiologies and Disease Processes as Compared to DVT as Secondary Diagnoses (SD)?
Viswanathan P, Gandhi T, Krishnamurti L. Does Deep Venous Thrombosis as Primary Admitting Diagnosis Represent Different Etiologies and Disease Processes as Compared to DVT as Secondary Diagnoses (SD)? Blood 2010, 116: 1540. DOI: 10.1182/blood.v116.21.1540.1540.Peer-Reviewed Original ResearchDeep venous thrombosisCongestive heart failureSecondary diagnosisPrimary diagnosisDisease processHeart failureVenous thrombosisVenous catheterizationAtrial fibrillationEndotracheal intubationInvasive proceduresDiagnosis of DVTPacked red cell transfusionNational Inpatient Sample databaseSerious medical morbidityRed cell transfusionUrinary tract infectionAge group 45Serious medical illnessTime of admissionICD-9 codesICD-9 codingCell transfusionInitial admissionTract infections
2007
Use of Rituximab for Refractory Immune Cytopenias Associated with Autoimmune Lymphoproliferative Syndrome (ALPS).
Dale J, Price S, Tretler J, Aldridge P, Montague S, Davis J, Gill F, Hartman K, Stork L, Gnarra D, Krishnamurti L, Puck J, Fleisher T, Rao V. Use of Rituximab for Refractory Immune Cytopenias Associated with Autoimmune Lymphoproliferative Syndrome (ALPS). Blood 2007, 110: 1319. DOI: 10.1182/blood.v110.11.1319.1319.Peer-Reviewed Original ResearchAutoimmune lymphoproliferative syndromeALPS patientsMycophenolate mofetilRituximab therapyDouble-negative T lymphocytesALPS phenotypeNegative T lymphocytesUse of rituximabCompletion of therapyRed cell transfusionAdult male patientsNIH Clinical CenterLong-term riskDurable normalizationPneumococcal sepsisPrednisone pulsesRefractory ITPRituximab infusionRituximab useWeekly vincristineCell transfusionHepatitis CImmune thrombocytopeniaPalpable spleenPolysaccharide vaccine